



**Supplemental Table 1.** Patient characteristics comparison between CAPOX+Bevacizumab (current study) and CAPOX (prior study Overman *et al.* [4])

Variable		CAPOX +Bevacizumab (n = 30)	CAPOX (n = 25)	P-value from Fisher exact test
Race	Non-white	8 (26.7%)	5 (20.0%)	0.75
	White	22 (73.3%)	20 (80.0%)	
Gender	Male	13 (43.3%)	14 (56.0%)	0.42
	Female	17 (56.7%)	11 (44.0%)	
Ampulla	No	23 (76.7%)	16 (64.0%)	0.23
	Yes	7 (23.3%)	9 (36.0%)	
Liver metastases	No	13 (43.3%)	13 (52.0%)	0.59
	Yes	17 (56.7%)	12 (48.0%)	
Peritoneal Metastases	No	22 (73.3%)	16 (64.0%)	0.56
	Yes	8 (26.7%)	9 (36.0%)	
Grade	Moderate	12 (40.0%)	12 (48.0%)	0.59
	Poor	18 (60.0%)	13 (52.0%)	
Response	No	15 (51.7%)	12 (48.0%)	0.79
	Yes	14 (48.3%)	13 (52.0%)	
		<b>Mean (std), median (min, max)</b>	<b>Mean (std), median (min, max)</b>	<b>Wilcoxon rank sum test</b>
Age (years)		60.3 (10.8), 63 (33, 78)	62.2 (9.0), 63 (41, 79)	0.55



**Supplemental Figure 1.** Kaplan Meier Estimates of overall survival and progression-free survival for CAPOX+Bevacizumab (current study) and CAPOX (prior study Overman *et al.* [4]).